FOUNDER

University of Florida, Juris Doctorate in Law
Masters of Accounting, BA in Accounting

Dustin is a leader within the psychedelic ecosystem and has been ranked by Psychedelic Invest as the Top 100 Most Influential People in Psychedelics. As a licensed attorney and CPA with a law firm that exclusively works in the cannabis and psychedelic space and as the founder of a leading non-profit that is paving the way for psychedelic legalization, Dustin is an expert in understanding and capitalizing on opportunities within highly regulated industries. Dustin has been featured in top publications (i.e. Forbes) for his deep knowledge, experience, and advocacy in the psychedelic space; and his law firm has been listed by Psychedelic Invest as one of the Five Psychedelic Law Firms You Should Have on Your Radar.

FOUNDER

Harvard Business School, MBA
Northwestern University, BA in Economics

Robert is a seasoned private equity investor with over 25 years of global private equity investment experience in a broad range of industries in the US, Latin America, Europe, and Asia. Robert has proven experience building and managing private markets investment platforms as a senior leader in institutional, family office and impact investment firms. Robert is also an experienced board member of numerous portfolio companies and investment committee member of several private equity funds. 

CLINICAL LEAD

BA in Nutritional and Health Science, University of Florida

DO, MPH, Nova Southeastern University

Double Board Certified in Physical Medicine and Rehabilitation and Pain Management  

Pain Management Specialist  

Investigates cannabis as a substitute for opioids and cannabis for pain in seniors 

Chair of Florida’s Medical Marijuana Advisory Committee

PSYCHIATRIC LEAD

BA in Economics, The University of Chicago
MD, Northwestern University

Certificate in Psychedelic Therapy and Research at the California Institute of Integral Studies

Lead Facilitator in FDA Phase 2 trial assessing effectiveness of a single dose of psilocybin for severe depression

FDA LEAD

BA in Biology, The University of Chicago 
JD, Catholic University (Washington, DC) 

FDA regulatory and transactional attorney advising life science, cannabis/hemp and psychedelics ventures 

Former Patent Advisor, Natural Products Branch, National Cancer Institute at NIH

Former Founder & CEO, Andes Pharmaceuticals Inc.

Author of Legal Guide to the Business of Marijuana (PLI Press, 2020)

COMMERCIALIZATION LEAD

CEO, BalinBac Therapeutics, Inc.

Start-up and pharmaceutical industry veteran, John M.H. Gregg, has extensive experience in forming and successfully exiting infectious disease companies. His expertise is in worldwide clinical development and commercialization of microbiological products, new anti-infectives, and oncology drugs, most recently with an FDA approval in September 2017 of Solosec (secnidazole). He has spent much of his career directing the commercialization efforts for a large number of antibiotic, anti-protozoal, anti-fungal and anti-viral drugs as well as therapeutics in multiple other therapeutic areas, including immunology, oncology, and neuroscience. He is an industry leader in biotech company development, serving as CEO of specialty infectious disease start-ups like his current company, BalinBac, now focused on developing direct antivirals for COVID-19.

INTELLECTUAL PROPERTY LEAD

Chief Legal Officer and General Counsel for Psygen and represents various cannabis and psychedelic businesses (e.g., GoodCap Pharmaceuticals) with various issues related to regulations and intellectual property

BSc and PhD in Biochemistry, University of Saskatchewan

LLB, University of Saskatchewan

Specialization in Patents and other Intellectual Property in the Psychedelic Industry

RESEARCH LEAD

BSc Biomedical Sciences, Newcastle University

MSc Clinical Neuropsychiatry, Kings College London

Ph.D Neuropsychopharmacology, Imperial College London

Rayyan is currently conducting his PhD with a medical research council fellowship under Professor David Nutt at Imperial College London in the Centre for Psychedelic Research and Neuropsychopharmacology. He is working across several clinical and brain imaging studies to assess the mechanisms of addiction in the human brain using neuroimaging. Rayyan is also working across studies developing novel pharmacological interventions, including classical and non-classical psychedelics, to treat a range of psychiatric conditions in early proof of concept and principle clinical studies.

SCIENTIFIC LEAD

CSO of Green Scientific Labs
Pharmacognosist and Ethnochemist

Focused on the standardization in cultivation, extraction and testing of Medicinal plants and marine invertebrates

Expertise in overall function of a laboratory from startup, method development, Federal, state, and ISO 17025 licensing, accreditation, and compliance

TECH LEAD

Matt is a healthcare technology executive who ran cross-functional business development, partnership and marketing teams at a top global medical device manufacturer, Stryker, and scaled multiple high-growth mental health startups to exit opportunities, including leading the B2B divisions at Headspace and Talkspace. Prior to building predictable, scalable, high-performing revenue machines, Matt graduated cum laude from the University of Florida with a degree in Neuroscience and Integrative Biology and a Master’s of Science in Management.

LEGAL ADVISOR

Amanda Barton is an active member of the Florida Bar and is admitted to practice in all U.S. District Courts and U.S. Bankruptcy Courts within the state of Florida.  Amanda has over ten years of legal experience handling complex corporate matters, with a strong focus on corporate governance, corporate finance, and regulatory compliance. 

Prior to joining Mr. Cannabis Law, Amanda had unique legal opportunities that have made her a well-versed, seasoned transactional business attorney.  Previously, she led the transactional department at The Law for All, P.A.

MARKETING LEAD

Samuel Baum is an accomplished marketing expert with a remarkable career spanning over 20 years. From international strategy to grassroots campaigns, his expertise in the field is unparalleled. Notable achievements include creating the renowned Psychedelic Club panel series, founding the successful Launch Sequence Agency, and serving as the Director of Marketing at Red Bull for six years.

Beyond his marketing prowess, Samuel's passion for arts and culture is evident through his involvement as a board member for Soho House and Nu Deco Ensemble. His visionary approach to marketing has earned him five "Best of Miami" Awards and a nomination for the prestigious "MasterMind Award." With an unwavering commitment to excellence and innovation, Samuel Baum continues to shape the marketing landscape, leaving an enduring impact on the industry and society as a whole